e Silva et al., 2019 - Google Patents
Mitochondrial dysfunction and changes in high-energy compounds in different cellular models associated to hypoxia: implication to schizophreniae Silva et al., 2019
View HTML- Document ID
- 8110391253422106950
- Author
- e Silva L
- Brito M
- Yuzawa J
- Rosenstock T
- Publication year
- Publication venue
- Scientific Reports
External Links
Snippet
Schizophrenia (SZ) is a multifactorial mental disorder, which has been associated with a number of environmental factors, such as hypoxia. Considering that numerous neural mechanisms depends on energetic supply (ATP synthesis), the maintenance of …
- 206010021143 Hypoxia 0 title abstract description 150
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving viable micro-organisms
- C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving viable micro-organisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| e Silva et al. | Mitochondrial dysfunction and changes in high-energy compounds in different cellular models associated to hypoxia: implication to schizophrenia | |
| Hacohen-Kleiman et al. | Activity-dependent neuroprotective protein deficiency models synaptic and developmental phenotypes of autism-like syndrome | |
| Harrington et al. | MEF2C regulates cortical inhibitory and excitatory synapses and behaviors relevant to neurodevelopmental disorders | |
| Yuskaitis et al. | Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome | |
| Li et al. | Hippocampal deficits in neurodevelopmental disorders | |
| Gandhi et al. | Dopamine induced neurodegeneration in a PINK1 model of Parkinson's disease | |
| Sahu et al. | Cellular senescence in the aging brain: a promising target for neurodegenerative diseases | |
| Zhou et al. | The mitochondrial unfolded protein response: A multitasking giant in the fight against human diseases | |
| Anand et al. | Dysregulated iron metabolism in C. elegans catp-6/ATP13A2 mutant impairs mitochondrial function | |
| Yamashiro et al. | AUTS2 governs cerebellar development, purkinje cell maturation, motor function and social communication | |
| Sawano et al. | Thyroid hormone-dependent development of the GABAergic pre-and post-synaptic components in the rat hippocampus | |
| Abtahi et al. | The distinctive role of tau and amyloid beta in mitochondrial dysfunction through alteration in Mfn2 and Drp1 mRNA Levels: A comparative study in Drosophila melanogaster | |
| Pakarinen et al. | MANF ablation causes prolonged activation of the UPR without neurodegeneration in the mouse midbrain dopamine system | |
| Fukuda et al. | Psychiatric behaviors associated with cytoskeletal defects in radial neuronal migration | |
| Jamal et al. | Rescue of altered HDAC activity recovers behavioural abnormalities in a mouse model of Angelman syndrome | |
| Wang et al. | Vitamin A supplementation ameliorates motor incoordination via modulating RORα in the cerebellum in a valproic acid-treated rat autism model with vitamin A deficiency | |
| Fuchs et al. | Pharmacotherapy with sertraline rescues brain development and behavior in a mouse model of CDKL5 deficiency disorder | |
| Onraet et al. | C. elegans as a model to study mitochondrial biology and disease | |
| Kishi et al. | Dissecting MECP2 function in the central nervous system | |
| Fumagalli et al. | The AMPA receptor potentiator Org 26576 modulates stress-induced transcription of BDNF isoforms in rat hippocampus | |
| Cooper et al. | Familial Parkinson's disease iPSCs show cellular deficits in mitochondrial responses that can be pharmacologically rescued | |
| Pinto et al. | Ablation of cytochrome c in adult forebrain neurons impairs oxidative phosphorylation without detectable apoptosis | |
| Cunha-Oliveira et al. | Integrative profiling of amyotrophic lateral sclerosis lymphoblasts identifies unique metabolic and mitochondrial disease fingerprints | |
| Luo et al. | Deletion of narfl leads to increased oxidative stress mediated abnormal angiogenesis and digestive organ defects in zebrafish | |
| Sabouri et al. | Unlocking the brain’s zinc code: implications for cognitive function and disease |